For those at high risk of NAION, alternative treatment options for diabetes and weight management may be considered
As healthcare professionals and patients work together to navigate the transition to this groundbreaking medication, the potential for improved outcomes and enhanced quality of life is truly exciting
Theres no single profile that defines a GLP-1 user
Clinical trials, including phase 2 and 3 studies, have reported significant improvements in liver histology, including MASH resolution and decreased hepatic fat content, with GLP-1RA therapy (6, 7)
Finally, clinicians should maintain a low threshold for evaluating patients who report unusual or severe gastrointestinal symptoms, as these may indicate inadvertent overdosing or other complications requiring intervention